Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 16/20 | 0.64 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.49 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24140773 | 0.89 | ERN1 (0.64) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL9861378 | 0.86 | ERN1 (0.60) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL15534494 | 0.86 | ERN1 (0.73) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL23094539 | 0.86 | ERN1 (0.60) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL9016537 | 0.84 | ERN1 (0.58) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL9860690 | 0.82 | ERN1 (0.57) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL30928263 | 0.80 | NFE2L2 (0.60) | ERN1KDM4EALDH1A1TDP1MAPT | |
| SCHEMBL1134649 | 0.79 | PRKDC (0.58) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL11999811 | 0.79 | ERN1 (0.60) | ERN1PRKDCKDM4EALDH1A1TSHR | |
| SCHEMBL11999813 | 0.79 | ERN1 (0.61) | ERN1PRKDCKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118743694-A | Application of bromophenol-chalcone compounds in medicines for treating type 2 diabetes | 山东大学 | 2024-10-08 | — | — | CN | disclosed |
| US-11820763-B2 | Bromophenol-pyrazoline compound and synthesis method and use thereof | Lead High Technology (QingDao) Co., Ltd (CN) | 2023-11-21 | — | — | US | disclosed |
| US-11820763-B2 | Bromophenol-pyrazoline compound and synthesis method and use thereof | Lead High Technology (QingDao) Co., Ltd (CN) | 2023-11-21 | — | — | US | disclosed |
| US-11820763-B2 | Bromophenol-pyrazoline compound and synthesis method and use thereof | Lead High Technology (QingDao) Co., Ltd (CN) | 2023-11-21 | — | — | US | disclosed |
| US-11752133-B2 | Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases | Shandong Linghai Biotechnology Co., Ltd. (CN) | 2023-09-12 | — | — | US | disclosed |
| US-11752133-B2 | Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases | Shandong Linghai Biotechnology Co., Ltd. (CN) | 2023-09-12 | — | — | US | disclosed |
| CN-116606256-A | Benzimidazole-4-carboxamide derivatives with selective PARP-1 inhibition effect | 山东大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-111848516-B | Bromophenol-pyrazoline compound and synthetic method and application thereof | 山东大学 | 2022-04-01 | — | — | CN | disclosed |
| US-20220041585-A1 | BROMOPHENOL-PYRAZOLINE COMPOUND AND SYNTHESIS METHOD AND USE THEREOF | LEAD HIGH TECHNOLOGY (QINGDAO) CO.,LTD (CN) | 2022-02-10 | — | — | US | disclosed |
| US-10947206-B2 | cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-6825208-B2 | SELECTIVE INHIBITORS OF SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR VIIA; MODULATION OF THE COAGULATION CASCADE. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-30 | — | — | US | disclosed |
| WO-2004069998-A2 | OXINDOLE DERIVATIVES AS ANTIMICROBIAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2004-08-19 | — | — | WO | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-20020065309-A1 | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists | AFFYMAX, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002011732-A1 | NOVEL BICYCLIC AND TRICYCLIC PYRROLIDINE DERIVATIVES AS GNRH ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-02-14 | — | — | WO | disclosed |
| EP-0481441-B1 | Novel cephem compounds, their preparation processes and antibacterial agents | KYORIN SEIYAKU KK (JP) | 1996-12-11 | — | — | EP | disclosed |
| US-5244892-A | Pseudomonas | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0481441-A2 | Novel cephem compounds, their preparation processes and antibacterial agents | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1992-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225110-A1 | Tetrahydroquinoline derivatives as antithrombotic agents | TFPI, TFPI2, SERPINC1 | ERN1 1774/4885PRKDC 2948/4885KDM4E 2375/4885 |
| US-11820763-B2 | Bromophenol-pyrazoline compound and synthesis method and use thereof | ACE, ACE2, PEPD | ERN1 932/4885PRKDC 3752/4885KDM4E 2368/4885 |
| US-10947206-B2 | cGAS antagonist compounds | CGAS, STING1, GLS2 | ERN1 2251/4885PRKDC 1829/4885KDM4E 4717/4885 |
| US-20020065309-A1 | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists | GNRHR, FSHR, LHCGR | ERN1 2242/4885PRKDC 3566/4885KDM4E 1021/4885 |
| US-20220041585-A1 | BROMOPHENOL-PYRAZOLINE COMPOUND AND SYNTHESIS METHOD AND USE THEREOF | ACE, ACE2, PEPD | ERN1 932/4885PRKDC 3752/4885KDM4E 2368/4885 |
| US-11752133-B2 | Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases | GTF3C3, GTF3C4, GTF3C2 | ERN1 924/4885PRKDC 2395/4885KDM4E 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.